Action on sickle cell retinopathy: the time is now

Dinah, Christiana; Greystoke, Brigit; Mueller, Isabella; Talks, James

doi:10.1038/s41433-021-01918-y

Cited by 11 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like other regions of the world, it is important that attention be drawn to visual complications of sickle cell retinopathy in sub-Saharan Africa, well designed protocols need to be developed, and a better understanding of factors associated with regression of neovascularization is much needed. Well-designed screening protocols are also required as well as better training for care givers [14][15][16].…”

Section: Discussionmentioning

confidence: 99%

A review of outcomes of laser photocoagulation for Goldberg stage 3 proliferative sickle cell retinopathy

Oderinlo¹,

Bulus²,

Umeh³

et al. 2022

J Global Med

View full text Add to dashboard Cite

Topic: A review of outcomes of laser photocoagulation for Goldberg stage 3 proliferative sickle cell retinopathy (PSR) in a Eye Foundation Hospital. Aims and objectives: To report regression of retina neovascularization and visual outcomes after prophylactic scatter retina laser photocoagulation for Goldberg stage 3 PSR in a tertiary private hospital in sub-Saharan Africa. Methods: A retrospective review of case files of patients who were treated with prophylactic scatter retina laser photocoagulation between January 2017 and June 2022 following a diagnosis of PSR in a Eye Foundation Hospital, Ikeja, Lagos, Nigeria, was done. Results: A total of 124 eyes of 62 patients with PSR were seen within the period under consideration. A majority of patients (49 (79.0%)) had hemoglobin (Hb) genotype SC, while 13 patients (21%) were Hb genotype SS. At presentation, 29 eyes (23.3%) had Goldberg stage 2 PSR, 55 eyes (44.4%) had Goldberg stage 3 PSR, 27 eyes (21.8%) had stage 4 PSR, while 13 eyes (10.5%) had stage 5 PSR. All 55 eyes (49.2%) with stage 3 PSR were treated with prophylactic retina laser photocoagulation. At the patients’ last clinic visit, 34 eyes (61.8%) had the same visual acuity (VA) as at presentation, 11 eyes (20%) had improvements in VA, while 10 eyes (18.2%) had worse VA. Laser treatment success (regression of seafan neovascularization) was seen in 50 eyes (90.9%), while five eyes (8.1%) had unsuccessful laser treatment. Conclusion: A high percentage (90.9%) of resolution of retina neovascularization secondary to PSR at stage 3 of Goldberg’s classification was seen after prophylactic scatter retina laser photocoagulation in our group of evaluated patients. Most patients (81.8%) maintained or had improvements in their visual acuities over the period of follow-up. More clinical research is required to further evaluate outcomes of laser photocoagulation for PSR.

show abstract

Section: Discussionmentioning

confidence: 99%

A review of outcomes of laser photocoagulation for Goldberg stage 3 proliferative sickle cell retinopathy

Oderinlo¹,

Bulus²,

Umeh³

et al. 2022

J Global Med

View full text Add to dashboard Cite

show abstract

“…SCD is estimated to affect approximately 100 000 people in the United States and over 3 million people worldwide [1]. Sickle cell retinopathy is an ocular manifestation of SCD caused by retinal vascular occlusion leading to retinal ischemia and can result in vascular proliferation and irreversible vision loss [2,3]. The clinical manifestations are classified as proliferative or nonproliferative sickle cell retinopathy based on the presence or absence of vascular proliferation, respectively.…”

Section: Introductionmentioning

confidence: 99%

Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy

Garg,

Scott

2024

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review To review the literature evaluating systemic medications for treatment of sickle cell disease (SCD) and their applications for sickle cell retinopathy. Recent Findings Prior studies have demonstrated the efficacy of traditional systemic therapies in reducing the risk of development of sickle cell retinopathy. Since 2017, several new and promising disease-modifying therapies for sickle cell disease have been approved for clinical use, including the first genetic therapies such as exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel). These treatments have shown promising results for systemic management but are not widely utilized due to limited access and high cost. The efficacy of these therapies for the prevention of sickle cell retinopathy remains unknown and opens the door to new avenues for research. Furthermore, the role of systemic therapy for the management of hemoglobin SC (HbSC) disease, which has milder systemic effects but higher likelihood of causing retinopathy, remains poorly understood. Summary Hydroxyurea has been a mainstay of systemic management of SCD with prior work suggesting its ability to reduce the likelihood of developing retinopathy. There are several new and potentially curative systemic therapies for SCD, though their role in retinopathy prevention and management has not been studied extensively. Future studies are necessary to understand the implications of these emerging therapies for sickle cell retinopathy.

show abstract

“…The retina, at the posterior aspect of the eye, is a neurovascular network responsible for photon capturing and preliminary visual information processing [1,2]. As an extension of the central nervous system, the retina offers a unique opportunity for noninvasive examination of the body's microvasculature [3] which can potentially reveal signs of systemic and retinal diseases [4,5]. The wall-to-lumen ratio (WLR), the ratio of blood vessel wall thickness (WTN) to lumen diameter (LD), is used to assess the health of these blood vessels [6].…”

Section: Introductionmentioning

confidence: 99%

Adaptive vessel tracing and segmentation in OCT enables robust quantification of blood vessel wall-to-lumen ratio in the retina

Adejumo,

Ma,

Son

et al. 2024

Ophthalmic Technologies XXXIV

View full text Add to dashboard Cite

The wall-to-lumen ratio (WLR) of retinal blood vessels promises a sensitive marker for functional assessment of eye conditions. However, in vivo measurement of vessel wall thickness and lumen diameter is still technically challenging, hindering the wide application of WLR in research and clinical settings. In this study, we demonstrate the feasibility of using optical coherence tomography (OCT) as one practical method for in vivo quantification of WLR in the retina. Based on three-dimensional vessel tracing, lateral en face and axial B-scan profiles of individual vessels were constructed. By employing adaptive depth segmentation that traces each blood vessel for en face OCT projection, the vessel wall thickness and lumen diameter could be reliably quantified. A comparative study of control and 5xFAD mice confirmed WLR as a sensitive marker of the eye condition.

show abstract

Action on sickle cell retinopathy: the time is now

Cited by 11 publications

References 26 publications

A review of outcomes of laser photocoagulation for Goldberg stage 3 proliferative sickle cell retinopathy

A review of outcomes of laser photocoagulation for Goldberg stage 3 proliferative sickle cell retinopathy

Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy

Adaptive vessel tracing and segmentation in OCT enables robust quantification of blood vessel wall-to-lumen ratio in the retina

Contact Info

Product

Resources

About